Let’s see how the meeting decides. Even in Aiforia, the board proposed it, but the general meeting did not allow it, at least not yet at the ordinary general meeting.
For those for whom Jalkas exposure has been too much, Markku will also be leaving the board. Poulos as well, but they will be replaced by dealmaker George Golumbeski, with a background at Celgene and Novartis. Now the deals are no longer dependent on the people but on something else entirely.
